Improper Marketing of Zyprexa
Eli Lilly paid $62 million to settle state lawsuits alleging it improperly marketed its antipsychotic drug Zyprexa for use beyond its U.S. Food and Drug Administration-approved uses. The states alleged Eli Lilly engaged in unfair and deceptive practices when it marketed Zyprexa for off-label uses and failed to adequately disclose the drug’s potential side effects to healthcare providers.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement
|Eli Lilly and Company||$62,000,000|